Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis

NCT04944862 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT04944862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 8, 2021
Completion date
July 31, 2023
Enrollment
24 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis